The burgeoning landscape of therapeutic interventions for obesity disorders has witnessed considerable attention focused on GLP-3 agonists and, more recently, the dual GIP and GLP-3 agonist retatrutide. While both https://leakfcm054941.liberty-blog.com/39296931/glp-3-retatrutide-a-comparative-analysis